JP Morgan Chase’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,449
| Closed | -$49.2K | – | 7933 |
|
|
2025
Q4 | $49.2K | Sell |
5,449
-742,639
| -99% | -$5.55M | ﹤0.01% | 6234 |
|
|
2025
Q3 | $2.33M | Buy |
748,088
+290,169
| +63% | +$769K | ﹤0.01% | 3970 |
|
|
2025
Q2 | $980K | Sell |
457,919
-586,222
| -56% | -$947K | ﹤0.01% | 4394 |
|
|
2025
Q1 | $1.2M | Buy |
1,044,141
+115,552
| +12% | +$198K | ﹤0.01% | 4225 |
|
|
2024
Q4 | $2.03M | Sell |
928,589
-78,930
| -8% | -$179K | ﹤0.01% | 4154 |
|
|
2024
Q3 | $2.2M | Buy |
1,007,519
+20,236
| +2% | +$46.5K | ﹤0.01% | 3933 |
|
|
2024
Q2 | $2.28M | Buy |
987,283
+33,810
| +4% | +$140K | ﹤0.01% | 3665 |
|
|
2024
Q1 | $5.24M | Buy |
953,473
+843,101
| +764% | +$3.86M | ﹤0.01% | 3064 |
|
|
2023
Q4 | $273K | Sell |
110,372
-49,059
| -31% | -$466K | ﹤0.01% | 5169 |
|
|
2023
Q3 | $5.54M | Sell |
159,431
-24,111
| -13% | -$834K | ﹤0.01% | 2753 |
|
|
2023
Q2 | $6.02M | Sell |
183,542
-50,108
| -21% | -$1.73M | ﹤0.01% | 2715 |
|
|
2023
Q1 | $7.83M | Buy |
233,650
+216,697
| +1,278% | +$8.43M | ﹤0.01% | 2490 |
|
|
2022
Q4 | $556K | Buy |
16,953
+4,705
| +38% | +$139K | ﹤0.01% | 4445 |
|
|
2022
Q3 | $428K | Buy |
12,248
+264
| +2% | +$5.84K | ﹤0.01% | 4562 |
|
|
2022
Q2 | $147K | Buy |
11,984
+4,391
| +58% | +$65.6K | ﹤0.01% | 5225 |
|
|
2022
Q1 | $103K | Sell |
7,593
-55,717
| -88% | -$744K | ﹤0.01% | 5496 |
|
|
2021
Q4 | $1.26M | Buy |
+63,310
| New | +$1.2M | ﹤0.01% | 4221 |
|
Other funds holding VTYX
JP Morgan Chase's VTYX Position: Q1 2026 in Review
JP Morgan Chase sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 5,449 shares — an estimated $49.2K sold.
JP Morgan Chase first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $7.83M in Q1 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- JP Morgan Chase reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 5,449 Ventyx Biosciences shares in Q1 2026, an estimated $49.2K.
- JP Morgan Chase first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- JP Morgan Chase's Ventyx Biosciences position peaked at $7.83M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.